IL21 and melanoma: Results are expected from clinical trials evaluating the safety and efficacy of combining IL-21 with other immunotherapeutic mediators: IL-21/anti-PD-1 against solid tumors (NCT01629758) and IL-21/ipilimumab against melanoma (NCT01489059).